




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 473/00, 473/18, 473/32, C07H 19/16, 19/167, 19/173, A61K 31/52, 31/70		A1	(11) International Publication Number: WO 99/09031
			(43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/SE98/01467		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 14 August 1998 (14.08.98)		Published With international search report.	
(30) Priority Data: 9702957-3 15 August 1997 (15.08.97) SE 9704147-9 12 November 1997 (12.11.97) SE 9800452-6 13 February 1998 (13.02.98) SE			
(71) Applicant (for all designated States except US): MEDIVIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ZHOU, Xiao-Xiong [SE/SE]; Kallkärrsvägen 12, S-141 41 Huddinge (SE). JOHANSSON, Nils-Gunnar [SE/SE]; Bäverstigen 19, S-150 23 Enköping (SE). WÄHLING, Horst [DE/SE]; Tempelriddarevägen 3, S-127 61 Skärholmen (SE).			
(74) Agent: MORRISON, Iain; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).			

(54) Title: NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV)



(57) Abstract

A compound of the formula (I), wherein: nuc is the residue of a nucleoside analogue bonded through its single hydroxy group on the cyclic or acyclic saccharide moiety, R₁ is hydroxy, amino or carboxy; optionally having esterified/amide bonded thereon; a C₄-C₂₂ saturated or unsaturated, optionally substituted fatty acid or alcohol, or an aliphatic L-amino acid; R₂ is the residue of an aliphatic L-amino acid; L₁ is a trifunctional linker group; L₂ is absent or a difunctional linker group; and pharmaceutically acceptable salts thereof have favourable pharmacological properties and are antivirally active.